A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

BACKGROUND: Cytoreductive nephrectomy is thought to improve survival in metastatic renal cell carcinoma (mRCC). As many patients are ineligible for major surgery, we hypothesized that SABR could be a safe alternative. METHODS: In this dose-escalation trial, inoperable mRCC patients underwent SABR ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa, Rohann J. M., Ahmad, Belal, Warner, Andrew, Johnson, Craig, MacKenzie, Mary J., Pautler, Stephen E., Bauman, Glenn S., Rodrigues, George B., Louie, Alexander V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859400/
https://www.ncbi.nlm.nih.gov/pubmed/29558966
http://dx.doi.org/10.1186/s13014-018-0992-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859400/
https://www.ncbi.nlm.nih.gov/pubmed/29558966
http://dx.doi.org/10.1186/s13014-018-0992-3

Ejemplares similares